CVKD
Cadrenal Therapeutics, Inc. Common Stock
Biotechnology
Market Cap$15M
5Y Perf.-85.4%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
CVKD vs PTGX vs IMVT vs ARDX
Revenue, margins, valuation, and 5-year total return — side by side.
PTGX
Protagonist Therapeutics, Inc.
Biotechnology
Market Cap$6.39B
5Y Perf.+647.6%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.88B
5Y Perf.+62.9%
ARDX
Ardelyx, Inc.
Biotechnology
Market Cap$1.66B
5Y Perf.+131.4%
CVKD vs PTGX vs IMVT vs ARDX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CVKD | PTGX | IMVT | ARDX |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $15M | $6.39B | $5.88B | $1.66B |
| Revenue (TTM) | $0.00 | $18M | $0.00 | $428M |
| Net Income (TTM) | $-9M | $-115M | $-464M | $-58M |
| Gross Margin | — | 100.0% | — | 91.9% |
| Operating Margin | — | -8.1% | — | -8.7% |
| Forward P/E | — | 25.8x | — | — |
| Total Debt | $0.00 | $10M | $98K | $212M |
| Cash & Equiv. | $4M | $128M | $714M | $68M |
CVKD vs PTGX vs IMVT vs ARDX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CVKD
PTGX
IMVT
ARDX
| Stock | Jan 23 | May 26 | Return |
|---|---|---|---|
| Cadrenal Therapeuti… (CVKD) | 100 | 14.6 | -85.4% |
| Protagonist Therape… (PTGX) | 100 | 747.6 | +647.6% |
| Immunovant, Inc. (IMVT) | 100 | 162.9 | +62.9% |
| Ardelyx, Inc. (ARDX) | 100 | 231.4 | +131.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CVKD vs PTGX vs IMVT vs ARDX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PTGX and ARDX are tied at the top with 2 categories each — the right choice depends on your priorities. Ardelyx, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. CVKD also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
CVKD
Cadrenal Therapeutics, Inc. Common Stock
The Quality Compounder
CVKD is the clearest fit if your priority is quality.
- 5.2% margin vs PTGX's -6.5%
Best for: quality
PTGX
Protagonist Therapeutics, Inc.
The Income Pick
PTGX carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.23
- 7.5% 10Y total return vs ARDX's 253.1%
- Lower volatility, beta 0.23, Low D/E 1.7%, current ratio 12.71x
- Beta 0.23, current ratio 12.71x
Best for: income & stability and long-term compounding
IMVT
Immunovant, Inc.
The Secondary Option
IMVT lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
ARDX
Ardelyx, Inc.
The Growth Play
ARDX is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 22.1%, EPS growth -52.9%, 3Y rev CAGR 98.4%
- 22.1% revenue growth vs PTGX's -89.4%
- -11.8% ROA vs CVKD's -217.7%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ARDX | 22.1% revenue growth vs PTGX's -89.4% |
| Quality / Margins | CVKD | 5.2% margin vs PTGX's -6.5% |
| Stability / Safety | PTGX | Beta 0.23 vs CVKD's 2.07 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | PTGX | +126.2% vs CVKD's -60.7% |
| Efficiency (ROA) | ARDX | -11.8% ROA vs CVKD's -217.7% |
CVKD vs PTGX vs IMVT vs ARDX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
Segment breakdown not available.
FY 2025
CVKD vs PTGX vs IMVT vs ARDX — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLARDXLAGGINGIMVT
Who Leads Where
ARDX leads in 2 of 6 categories
PTGX leads 1 • CVKD leads 0 • IMVT leads 0 • 2 tied
Explore the data ↓IMVTImmunovant, Inc.
0leads
CVKDCadrenal Therapeutics…
0leads
PTGXProtagonist Therapeut…
1leads
ARDXArdelyx, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs PTGXvs CVKDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ARDX4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ARDX3/8
Total Returns1Y, 3Y, 5Y total returns with dividends
PTGX5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ARDX leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ARDX and IMVT operate at a comparable scale, with $428M and $0 in trailing revenue. Profitability is closely matched — net margins range from -13.6% (ARDX) to -6.5% (PTGX). On growth, ARDX holds the edge at +27.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CVKDCadrenal Therapeu… | PTGXProtagonist Thera… | IMVTImmunovant, Inc. | ARDXArdelyx, Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $18M | $0 | $428M |
| EBITDAEarnings before interest/tax | -$12M | -$141M | -$487M | -$35M |
| Net IncomeAfter-tax profit | -$9M | -$115M | -$464M | -$58M |
| Free Cash FlowCash after capex | -$11M | -$116M | -$423M | -$37M |
| Gross MarginGross profit ÷ Revenue | — | +100.0% | — | +91.9% |
| Operating MarginEBIT ÷ Revenue | — | -8.1% | — | -8.7% |
| Net MarginNet income ÷ Revenue | — | -6.5% | — | -13.6% |
| FCF MarginFCF ÷ Revenue | — | -6.6% | — | -8.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -100.0% | — | +27.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +50.2% | +126.3% | +19.7% | +11.8% |
ARDX leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — CVKD and PTGX and ARDX each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | CVKDCadrenal Therapeu… | PTGXProtagonist Thera… | IMVTImmunovant, Inc. | ARDXArdelyx, Inc. |
|---|---|---|---|---|
| Market CapShares × price | $15M | $6.4B | $5.9B | $1.7B |
| Enterprise ValueMkt cap + debt − cash | $11M | $6.3B | $5.2B | $1.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.92x | -48.47x | -10.60x | -26.08x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 25.80x | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 138.86x | — | 4.08x |
| Price / BookPrice ÷ Book value/share | 4.43x | 10.28x | 6.20x | 9.79x |
| Price / FCFMarket cap ÷ FCF | — | 113.94x | — | — |
Evenly matched — CVKD and PTGX and ARDX each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
ARDX leads this category, winning 3 of 8 comparable metrics.
Profitability & Efficiency
PTGX delivers a -17.8% return on equity — every $100 of shareholder capital generates $-18 in annual profit, vs $-3 for CVKD. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARDX's 1.27x. On the Piotroski fundamental quality scale (0–9), PTGX scores 4/9 vs CVKD's 1/9, reflecting mixed financial health.
| Metric | CVKDCadrenal Therapeu… | PTGXProtagonist Thera… | IMVTImmunovant, Inc. | ARDXArdelyx, Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -3.2% | -17.8% | -47.1% | -38.1% |
| ROA (TTM)Return on assets | -2.2% | -16.5% | -44.1% | -11.8% |
| ROICReturn on invested capital | — | -21.8% | — | -10.7% |
| ROCEReturn on capital employed | -2.6% | -23.9% | -66.1% | -10.6% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 | 2 | 3 |
| Debt / EquityFinancial leverage | — | 0.02x | 0.00x | 1.27x |
| Net DebtTotal debt minus cash | -$4M | -$118M | -$714M | $144M |
| Cash & Equiv.Liquid assets | $4M | $128M | $714M | $68M |
| Total DebtShort + long-term debt | $0 | $10M | $98,000 | $212M |
| Interest CoverageEBIT ÷ Interest expense | — | — | — | -0.28x |
ARDX leads this category, winning 3 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
PTGX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ARDX five years ago would be worth $41,341 today (with dividends reinvested), compared to $985 for CVKD. Over the past 12 months, PTGX leads with a +126.2% total return vs CVKD's -60.7%. The 3-year compound annual growth rate (CAGR) favors PTGX at 58.5% vs CVKD's -34.1% — a key indicator of consistent wealth creation.
| Metric | CVKDCadrenal Therapeu… | PTGXProtagonist Thera… | IMVTImmunovant, Inc. | ARDXArdelyx, Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -16.9% | +14.0% | +11.7% | +10.2% |
| 1-Year ReturnPast 12 months | -60.7% | +126.2% | +102.4% | +86.3% |
| 3-Year ReturnCumulative with dividends | -71.4% | +298.6% | +49.8% | +61.8% |
| 5-Year ReturnCumulative with dividends | -90.1% | +251.2% | +84.4% | +313.4% |
| 10-Year ReturnCumulative with dividends | -90.1% | +749.2% | +190.9% | +253.1% |
| CAGR (3Y)Annualised 3-year return | -34.1% | +58.5% | +14.4% | +17.4% |
PTGX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PTGX and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
PTGX is the less volatile stock with a 0.23 beta — it tends to amplify market swings less than CVKD's 2.07 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 96.2% from its 52-week high vs CVKD's 36.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CVKDCadrenal Therapeu… | PTGXProtagonist Thera… | IMVTImmunovant, Inc. | ARDXArdelyx, Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.07x | 0.23x | 1.36x | 1.05x |
| 52-Week HighHighest price in past year | $16.50 | $107.84 | $30.09 | $8.40 |
| 52-Week LowLowest price in past year | $4.20 | $41.60 | $13.36 | $3.21 |
| % of 52W HighCurrent price vs 52-week peak | +36.9% | +92.1% | +96.2% | +80.7% |
| RSI (14)Momentum oscillator 0–100 | 52.7 | 46.9 | 50.6 | 64.8 |
| Avg Volume (50D)Average daily shares traded | 53K | 747K | 1.4M | 3.6M |
Evenly matched — PTGX and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: PTGX as "Buy", IMVT as "Buy", ARDX as "Buy". Consensus price targets imply 150.7% upside for ARDX (target: $17) vs 16.1% for PTGX (target: $115).
| Metric | CVKDCadrenal Therapeu… | PTGXProtagonist Thera… | IMVTImmunovant, Inc. | ARDXArdelyx, Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $115.40 | $45.50 | $17.00 |
| # AnalystsCovering analysts | — | 26 | 23 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.9% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ARDX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PTGX leads in 1 (Total Returns). 2 tied.
Best OverallArdelyx, Inc. (ARDX)Leads 2 of 6 categories
Loading custom metrics...
CVKD vs PTGX vs IMVT vs ARDX: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is CVKD or PTGX or IMVT or ARDX a better buy right now?
For growth investors, Ardelyx, Inc.
(ARDX) is the stronger pick with 22. 1% revenue growth year-over-year, versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). Analysts rate Protagonist Therapeutics, Inc. (PTGX) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CVKD or PTGX or IMVT or ARDX?
Over the past 5 years, Ardelyx, Inc.
(ARDX) delivered a total return of +313. 4%, compared to -90. 1% for Cadrenal Therapeutics, Inc. Common Stock (CVKD). Over 10 years, the gap is even starker: PTGX returned +749. 2% versus CVKD's -90. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CVKD or PTGX or IMVT or ARDX?
By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc.
(PTGX) is the lower-risk stock at 0. 23β versus Cadrenal Therapeutics, Inc. Common Stock's 2. 07β — meaning CVKD is approximately 793% more volatile than PTGX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 127% for Ardelyx, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CVKD or PTGX or IMVT or ARDX?
By revenue growth (latest reported year), Ardelyx, Inc.
(ARDX) is pulling ahead at 22. 1% versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). On earnings-per-share growth, the picture is similar: Cadrenal Therapeutics, Inc. Common Stock grew EPS 23. 9% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Over a 3-year CAGR, ARDX leads at 98. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CVKD or PTGX or IMVT or ARDX?
Cadrenal Therapeutics, Inc.
Common Stock (CVKD) is the more profitable company, earning 0. 0% net margin versus -282. 8% for Protagonist Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CVKD leads at 0. 0% versus -343. 6% for PTGX. At the gross margin level — before operating expenses — PTGX leads at 97. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CVKD or PTGX or IMVT or ARDX more undervalued right now?
Analyst consensus price targets imply the most upside for ARDX: 150.
7% to $17. 00.
07Which pays a better dividend — CVKD or PTGX or IMVT or ARDX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is CVKD or PTGX or IMVT or ARDX better for a retirement portfolio?
For long-horizon retirement investors, Protagonist Therapeutics, Inc.
(PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 23), +749. 2% 10Y return). Cadrenal Therapeutics, Inc. Common Stock (CVKD) carries a higher beta of 2. 07 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PTGX: +749. 2%, CVKD: -90. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CVKD and PTGX and IMVT and ARDX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CVKD is a small-cap quality compounder stock; PTGX is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; ARDX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.